RecruitingPhase 3NCT06499857

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Sponsor

University of Chicago

Enrollment

200 participants

Start Date

Apr 14, 2025

Study Type

INTERVENTIONAL

Conditions

Atrial Fibrillation Overweight or Obesity

Summary

The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether semaglutide (the active ingredient in Ozempic/Wegovy) can reduce atrial fibrillation (AFib) — an irregular heartbeat — in people with obesity, by helping them lose body fat, particularly around the heart. **You may be eligible if...** - You are between 18 and 75 years old with a BMI of 30 or higher (obese) - You have paroxysmal (comes and goes) or persistent AFib - You may or may not be scheduled for catheter ablation (a procedure to correct AFib) - If you have type 2 diabetes, your HbA1c is ≤ 10% and you are managed with oral medications or basal insulin only **You may NOT be eligible if...** - You have type 1 diabetes or are on complex insulin regimens - You have serious kidney, liver, or heart failure - You have a personal or family history of certain thyroid cancers or pancreatitis - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.